New drugs: doripenem, raltegravir, and ixabepilone.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001424:Bacterial Infections / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D015780:Carbapenems / Q000008:administration & dosage* / Q000009:adverse effects; D000077726:Doripenem; D034261:Epothilones / Q000008:administration & dosage* / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009930:Organic Chemicals / Q000008:administration & dosage* / Q000009:adverse effects; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D015780:Carbapenems; D034261:Epothilones; D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000077726:Doripenem; C430592:ixabepilone